"A West Virginia federal district court’s decision that certain claims of a Biogen patent directed to the multiple sclerosis treatment drug Tecfidera were invalid for lack of written description support was not clearly erroneous" http://patentblog.kluweriplaw.com/2021/12/30/patent-case-biogen-international-gmbh-v-mylan-pharmaceuticals-inc-usa/ #usspto #cafc #fakepatents
